Episodic Cluster Headache Campaign image

Emgality provided a ≥50% reduction from baseline in weekly cluster headache attacks in most patients at Week 31

  • 71.4% of patients on Emgality 300 mg (N=49) experienced a ≥50% response from baseline vs 52.6% of patients on placebo (N=57) (p=0.046)

Emgality reduced the number of weekly cluster headache attacks by an average of 8.7 vs. 5.2 with placebo over Weeks 1 to 3 (baseline 17.8 vs 17.3) (p=0.036)1

See the Emgality Episodic Cluster Headache Study Design

INDICATION
Emgality is indicated for the treatment of episodic cluster headache in adults.

Emgality is the first and only calcitonin gene-related peptide (CGRP) antibody FDA approved for the treatment of episodic cluster headache in adults1,2

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Explore the Efficacy for Emgality or Download Savings Cards for Eligible Patients


References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 04JUN2019